NCT07452120 DIPB vs. SIFIB for Postoperative Analgesia After Hip Surgery
| NCT ID | NCT07452120 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sivas Numune Hospital |
| Condition | Hip Arthroplasty |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2026-03-27 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2026-03-27 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized, double-blind clinical trial aims to compare the effectiveness of the Deep Iliacus Plane Block (DIPB) and the Suprainguinal Fascia Iliaca Block (SIFIB) for postoperative pain control in patients undergoing primary total hip arthroplasty. Effective analgesia after hip surgery is essential for early mobilization, reduction of complications, and improved recovery outcomes. Seventy patients scheduled for elective hip arthroplasty under spinal anesthesia will be randomly assigned to receive either DIPB or SIFIB at the end of surgery. Postoperative pain scores, opioid consumption, motor block, and block-related complications will be evaluated over a 48-hour period. The study aims to determine whether DIPB provides superior or comparable analgesia with reduced motor blockade compared to SIFIB, thereby contributing to safer and more comprehensive postoperative pain management in hip surgery patients.
Eligibility Criteria
Inclusion Criteria: * Patients aged ≥18 years * ASA physical status I-III * Scheduled for elective primary total hip arthroplasty under spinal anesthesia * Ability to understand the study procedures and provide informed consent Exclusion Criteria: * Coagulation disorders or anticoagulant therapy contraindicating regional anesthesia * Infection at the block application site * Hemodynamic instability * Known allergy to local anesthetics * Pre-existing significant neurological or motor deficits in the lower extremities * Cognitive impairment preventing pain assessment * Refusal to participate or inability to provide informed consent
Contact & Investigator
Fatih BALCI
PRINCIPAL INVESTIGATOR
Sivas Numune Hospital, Department of Anesthesiology and Reanimation
Frequently Asked Questions
Who can join the NCT07452120 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hip Arthroplasty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07452120 currently recruiting?
Yes, NCT07452120 is actively recruiting participants. Contact the research team at fatihbalci05@gmail.com for enrollment information.
Where is the NCT07452120 trial being conducted?
This trial is being conducted at Sivas, Turkey (Türkiye), Sivas, Turkey (Türkiye).
Who is sponsoring the NCT07452120 clinical trial?
NCT07452120 is sponsored by Sivas Numune Hospital. The principal investigator is Fatih BALCI at Sivas Numune Hospital, Department of Anesthesiology and Reanimation. The trial plans to enroll 70 participants.